Technical Analysis for CELC - Celcuity Inc.

Grade Last Price % Change Price Change
grade B 23.47 0.73% 0.17
CELC closed up 0.73 percent on Friday, May 24, 2019, on 1.23 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CELC trend table...

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish 0.73%
NR7 Range Contraction 0.73%
Upper Bollinger Band Walk Strength 0.73%
Overbought Stochastic Strength 0.73%
Upper Bollinger Band Touch Strength 0.73%

Older signals for CELC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Celcuity, Inc. is a United States-based early stage biotechnology company. The Company develops tests that functionally analyze diseased live cells. The Company has developed CELx Pathway Profile technology, which combines advancements in primary tissue research with a method of measuring a targeted therapy's functional pathway effect on live and diseased patient cells. The Company offers functional cellular analysis platform that assesses the functionality of the disease-related signaling pathways of patient's diseased cells ex vivo and determines whether a drug therapy has the effect on diseased cells. The Company's CELx test is designed to determine whether a pathway is functional to therapeutic intervention without regard to the exact mechanism a patient's tumor may have developed to resist the therapeutic effect. The Company’s diagnostic approach helps to identify cancer subtypes.
Biotechnology Cancer Biology Stem Cells Cell Biology Cell Signaling Signal Transduction Drug Therapy Systems Biology Patient's Tumor
Is CELC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 31.0
52 Week Low 18.28
Average Volume 6,196
200-Day Moving Average 24.0636
50-Day Moving Average 21.8938
20-Day Moving Average 22.322
10-Day Moving Average 22.689
Average True Range 0.9183
ADX 15.87
+DI 28.9211
-DI 20.6697
Chandelier Exit (Long, 3 ATRs ) 21.2451
Chandelier Exit (Short, 3 ATRs ) 23.1228
Upper Bollinger Band 23.9094
Lower Bollinger Band 20.7346
Percent B (%b) 0.86
BandWidth 14.22274
MACD Line 0.4289
MACD Signal Line 0.2488
MACD Histogram 0.18
Fundamentals Value
Market Cap 228.18 Million
Num Shares 9.72 Million
EPS -0.02
Price-to-Earnings (P/E) Ratio -1173.50
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.21
Resistance 3 (R3) 24.13 23.80 24.09
Resistance 2 (R2) 23.80 23.61 23.84 24.04
Resistance 1 (R1) 23.63 23.49 23.72 23.72 24.00
Pivot Point 23.31 23.31 23.35 23.35 23.31
Support 1 (S1) 23.14 23.12 23.22 23.22 22.94
Support 2 (S2) 22.81 23.00 22.85 22.90
Support 3 (S3) 22.65 22.81 22.85
Support 4 (S4) 22.73